NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Highly Specialised Technologies Evaluation Committee (HSTEC) meeting minutes

**Minutes:** Confirmed

**Date:** Wednesday 10 April 2024

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr Paul Arundel (Chair) Present for all items
2. Emtiyaz Chowdhury Items 5.1.1 to 5.2.2
3. Professor Iolo Doull Present for all items
4. Tina Garvey Present for all items
5. Professor Jonathan Ives Present for all items
6. Andrew Makin Items 1.1 to 4.2.2
7. Stuart Mealing Present for all items
8. Sara Payne Present for all items
9. Angharad Shambler Present for all items
10. Professor Ed Wilson Present for all items

NICE staff (key players) present

Jasdeep Hayre, Associate Director Present for all items

Celia Mayers, Project Manager Present for all items

Christopher Griffiths, Health Technology Assessment Adviser

 Items 1.1 to 4.2.2

Kirsty Pitt, Health Technology Assessment Analyst Items 1.1 to 4.2.2

Caron Jones, Health Technology Assessment Adviser Items 5.1.1 to 5.2.2

Summaya Mohammad, Health Technology Assessment Analyst

 Items 5.1.1 to 5.2.2

External assessment group representatives present

James Mahon, Liverpool Reviews and Implementation Group

 Items 1.1 to 4.1.3

Rebecca Bresnahan, Liverpool Reviews and Implementation Group

 Items 1.1 to 4.1.3

Claire Rothery, Centre for Reviews and Dissemination and Centre for Health Economics, York Items 5.1.1 to 5.1.3

Mark Rogers, Centre for Reviews and Dissemination and Centre for Health Economics, York Items 5.1.1 to 5.1.3

Clinical, Patient & NHS England experts present

Professor Peter Clark, NHSE Clinical Lead for CDF Items 1.1 to 4.2.2

Kirstie Purnell, Patient Expert nominated by Association for Multiple Endocrine Neoplasia Disorders Items 1.1 to 4.1.3

Professor Jonathan Wadsley, Consultant Clinical Oncologist, Clinical Expert nominated by Eli Lilly Items 1.1 to 4.1.3

Dr Kee Howe Wong, Consultant Clinical Oncologist, Clinical Expert nominated by Eli Lilly

 Items 1.1 to 4.1.3

Louise Peacock, Patient Expert nominated by PNH Support

 Items 5.1.1 to 5.1.3

Alex Naylor, Trustee at PNH Support, Patient Expert nominated by PNH Support

 Items 5.1.1 to 5.1.3

Dr Austin Kulasekararaj, Consultant Haematologist and Lead for Kings National PNH service, Clinical Expert nominated by PNH Support and Novartis

 Items 5.1.1 to 5.1.3

Dr Morag Griffin, Joint service lead PNH Leeds, Clinical Expert, nominated by National PNH Service, Royal College of Pathologists, and Novartis Items 5.1.1 to 5.1.3

*Please note that alongside the attendees listed in this document, there were additional NICE Staff present in this meeting. These attendees were not involved in the decision making or discussions.*

## Minutes

### Introduction to the meeting

* 1. The Chair, Dr Paul Arundel, welcomed members of the committee and other attendees present to the meeting.
	2. The Chair noted apologies from Carrie Gardner, Sarah Davis and Dr Shehla Mohammed.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Thursday 7 March 2024.

### Evaluation of selpercatinib for untreated advanced thyroid cancer with RET alterations [ID6132]

* 1. Part 1 – Open session
		1. The Chair, Dr Paul Arundel, welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Eli Lilly.
		2. The Chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta11047).
		3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Professor Ed Wilson, Professor Iolo Doull, and Tina Garvey.
	2. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta11047>

### Evaluation of iptacopan for treating paroxysmal nocturnal haemoglobinuria [ID6176]

* 1. Part 1 – Open session
		1. The Chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Novartis Pharmaceuticals.
		2. The Chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta11132).
		3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Emtiyaz Chowdhury and Professor Jonathan Ives.
	2. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta11132>

### Date of the next meeting

The next meeting of the Highly Specialised Technologies Evaluation Committee (HSTEC) will be held on Wednesday 8 April 2024 and will start promptly at 09:00am.